Invention is central to Quanterix’s fully automated Simoa HD-1 Analyzer that provides a 1000-fold improvement in sensitivity for measuring proteins over conventional methods.
Quanterix Issued Key Patent for Simoa™ Technology
Quanterix Corporation, developer of the Single Molecule Array (Simoa) technology, announced today that it had been issued a US Patent for ultra-sensitive detection of molecules. The patent issue marks another milestone for Quanterix and highlights the achievements of the company’s scientific team for developing a truly novel approach to single molecule immunoassays. The ability to trap individual molecules in arrays of femtoliter wells and to count each one in a digital fashion allows measurement of proteins or nucleic acids at sub-femtomolar concentrations with great precision. This revolutionary approach enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications that address significant unmet needs in life science research, companion diagnostics, specialty in-vitro diagnostics, blood screening, food testing and biothreat detection.
“The issuance of this patent further increases the value of the company’s proprietary Simoa platform,” said Paul Chapman, President and CEO. “Strong IP protection will allow us to introduce this broadly applicable ultra-sensitive and ultra-precise detection platform for a number of high value biomarker applications. Simoa holds the promise of making the invisible visible and thereby enabling scientific breakthroughs in cancer research, neurology, cardiology, inflammation and many other important fields.”
Quanterix is incorporating the Simoa technology into a fully automated analyzer that will be commercially available as a research-use-only instrument in 2013.
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts.